LivaNova vs TransMedics
LIVN and TMDX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LIVN and TMDX compare
LivaNova is the larger company, worth 1.6 times as much as TransMedics ($5.1B against $3.3B).
On earnings, TransMedics is cheaper: it trades at 24.4× trailing earnings, against 27.1× for LivaNova.
TransMedics grew revenue faster over the last twelve months (25.8% versus 12.4% for LivaNova).
TransMedics keeps more of each dollar of sales as profit, with a net margin of 22.7% compared with 12.8% at LivaNova.
TransMedics scores higher on the StockData Score (14 against 13 for LivaNova), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LIVN | TMDX |
|---|---|---|
| Size and price | ||
| Market cap | $5.1B | $3.3B |
| Share price | $91.92 | $93.91 |
| Change, 1 year | 66.0% | −18.3% |
| Change, 5 years | 10.3% | 329% |
| Beta (5Y) | 0.83 | 0.77 |
| Employees | 3,300 | 898 |
| StockData Score | ||
| Total score | 13 | 14 (better) |
| Valuation score | 0 | 5 (better) |
| Growth score | 4 (better) | 2 |
| Performance score | 4 (better) | 3 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 27.1× | 24.4× (better) |
| P/S | 3.4× (better) | 4.9× |
| P/B | 3.8× (better) | 6.3× |
| EV/EBITDA | 25.8× | 23.8× (better) |
| P/FCF | 34.1× (better) | 41.2× |
| FCF yield | 2.9% (better) | 2.4% |
| Fair value | $69.65 | $131.38 |
| Margin of safety | −32.0% | 28.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 12.4% | 25.8% (better) |
| Revenue growth, 5Y average | 8.2% | 88.2% (better) |
| Net income growth (TTM) | – | 112% |
| EPS growth (TTM) | – | 99.5% |
| Profitability | ||
| Gross margin | 68.1% (better) | 58.7% |
| Operating margin | 12.7% (better) | 12.2% |
| Net margin | 12.8% | 22.7% (better) |
| FCF margin | 10.1% | 11.8% (better) |
| Return on equity | 15.4% | 36.3% (better) |
| Return on invested capital | 18.2% | – |
| Financial health | ||
| Debt / equity | 0.22 | 0.04 (better) |
| Net debt / EBITDA | −1.19 | −3.84 |
| Interest coverage | 5.0× (better) | 3.8× |
| Current ratio | 1.45 | 6.62 (better) |
| Altman Z-score | 2.71 | 2.91 (better) |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 108% | 100% |
| Held by insiders | 0.48% | 3.9% |
| Insider net buying, 12 months | −$1.3M (better) | −$4.2M |
| Short interest, % of float | 11.6% | 26.6% |
Go deeper
- LIVN stock overview
- LIVN income statement
- LIVN valuation and score
- TMDX stock overview
- TMDX income statement
- TMDX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.